The EPS beat and BLA submission timeline are strong catalysts, but historical T+20 performance on LRMR reports is poor (avg -7.9%). Monitor topline OL data in Q2 2026 and FDA Type B meeting outcome for BLA readiness. The $200.4M cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company advanced its BLA for nomlabofusp toward accelerated approval, planning a rolling submission starting June 2026 with topline open-label data expected Q2 2026. Cash of $200.4M provides runway into Q2 2027, but the stock's historical T+20 performance on prior reports has been poor (avg -7.9%).
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.31 vs consensus -$0.57 (45.6% beat)
- Net loss $29.6M vs $29.3M YoY; R&D expenses $25.0M down from $26.6M
- Cash, cash equivalents and marketable securities $200.4M as of March 31, 2026
- Planning rolling BLA submission for nomlabofusp starting June 2026; topline OL data expected Q2 2026
- Breakthrough Therapy Designation granted by FDA in February 2026
- $115M public offering completed in February 2026, net proceeds $107.6M
- Projected cash runway into Q2 2027
Financial Impact
EPS beat of 45.6% vs consensus; cash position $200.4M; net loss $29.6M
Risk Factors
- BLA submission and FDA approval are uncertain; regulatory delays or negative feedback could reverse gains
- Historical T+20 performance on LRMR reports shows avg -7.9% return, suggesting market may not sustain bullish momentum
- No revenue; pre-commercial stage with high cash burn ($29.6M/quarter)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3294760 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 14, 2026 20w ago | 8-K | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.97 (−23.65%) |
May 14, 2026 20w ago | Press Release | $3.89 $4.01 | ▲ +3.08% | ▼ −0.50% | $2.97 (−23.65%) |
Mar 19, 2026 28w ago | Press Release | $4.47 $3.59 | ▼ −19.69% | ▼ −34.03% | $2.97 (−33.56%) |
Feb 27, 2026 31w ago | 8-K | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
Feb 27, 2026 31w ago | Insider Cluster | $5.31 $3.47 | ▼ −34.65% | ▼ −44.04% | $2.97 (−44.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access